Verition Fund Management
SNDX icon

Verition Fund Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Verition Fund Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.67M Buy
+304,939
New +$6.34M 0.03% 525
2026
Q1 		– Sell
-18,460
Closed -$388K – 3428
2025
Q4 		$388K Buy
18,460
+1,281
+7% +$22.3K ﹤0.01% 2848
2025
Q3 		$264K Sell
17,179
-108,166
-86% -$1.42M ﹤0.01% 3357
2025
Q2 		$1.17M Buy
125,345
+90,308
+258% +$994K 0.01% 2355
2025
Q1 		$430K Buy
+35,037
New +$494K ﹤0.01% 2672
2024
Q4 		– Sell
-79,341
Closed -$1.53M – 3502
2024
Q3 		$1.53M Sell
79,341
-65,225
-45% -$1.35M 0.01% 1594
2024
Q2 		$2.97M Sell
144,566
-202,296
-58% -$4.23M 0.02% 1040
2024
Q1 		$8.26M Buy
346,862
+203,596
+142% +$4.54M 0.06% 409
2023
Q4 		$3.1M Buy
143,266
+128,266
+855% +$1.97M 0.02% 632
2023
Q3 		$218K Buy
+15,000
New +$284K ﹤0.01% 1931
2022
Q4 		– Sell
-10,737
Closed -$258K – 2681
2022
Q3 		$258K Buy
+10,737
New +$241K ﹤0.01% 2334
2021
Q1 		– Sell
-88,595
Closed -$1.97M – 1752
2020
Q4 		$1.97M Buy
+88,595
New +$1.84M 0.02% 378

Other funds holding SNDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Verition Fund Management's SNDX Position: Q2 2026 in Review

Verition Fund Management opened a new position in Syndax Pharmaceuticals (SNDX) in Q2 2026: 304,939 shares worth $6.67M. The stake represents 0.03% of the portfolio and ranks #525 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in SNDX as recently as Q4 2025.

Verition Fund Management first reported a position in SNDX in Q4 2020 and has held it in 12 quarters since. The position peaked at $8.26M in Q1 2024. 243 funds tracked by Wall St. Rank hold SNDX as of Q2 2026.

  • Verition Fund Management held 304,939 shares of Syndax Pharmaceuticals worth $6.67M as of Q2 2026.
  • Syndax Pharmaceuticals was a new Verition Fund Management position in Q2 2026.
  • Syndax Pharmaceuticals made up 0.03% of Verition Fund Management's portfolio in Q2 2026, its #525 holding.
  • Verition Fund Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and has held it in 12 quarters since.
  • Verition Fund Management's Syndax Pharmaceuticals position peaked at $8.26M in Q1 2024.
  • 243 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.